Mesencephalic corticospinal atrophy predicts baseline deficit but not response to unilateral or bilateral arm training in chronic stroke by Globas, C et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2011
Mesencephalic corticospinal atrophy predicts baseline deficit but not
response to unilateral or bilateral arm training in chronic stroke
Globas, C; Lam, J M; Zhang, W; Imanbayev, A; Hertler, B; Becker, C; Whitall, J; McCombe-Waller, S;
Mori, S; Hanley, D F; Luft, A R
Abstract: Larger lesions, internal capsule lesions, and those overlapping the pyramidal tract are associated
with greater CST atrophy. CST atrophy explains in part the variability of baseline deficits but does not
seem to predict the response to BATRAC or unilateral arm training on upper-extremity function.
DOI: 10.1177/1545968310382001
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-43374
Accepted Version
Originally published at:
Globas, C; Lam, J M; Zhang, W; Imanbayev, A; Hertler, B; Becker, C; Whitall, J; McCombe-Waller,
S; Mori, S; Hanley, D F; Luft, A R (2011). Mesencephalic corticospinal atrophy predicts baseline deficit
but not response to unilateral or bilateral arm training in chronic stroke. Neurorehabilitation and Neural
Repair, 25(1):81-87. DOI: 10.1177/1545968310382001
CST atrophy in chronic stroke – 1 
Mesencephalic corticospinal atrophy predicts 
baseline deficit but not response to uni- or 
bilateral arm training in chronic stroke 
Christoph Globas MD1,2,3, Judith M. Lam1,3 , Weihong Zhang MD, PhD4, Anuar 
Imanbayev4, Benjamin Hertler MD1, Clemens Becker MD2, Jill Whitall PhD5, Sandy 
McCombe-Waller PhD5, Susumu Mori PhD4, Daniel F. Hanley MD6, Andreas R. Luft 
MD1, 6 
 
1 Clinical Neurorehabilitation, Department of Neurology, University of Zürich, Frauenklinikstr. 26, 
Zürich, Switzerland 
2 Clinic of Geriatric Rehabilitation, Robert Bosch Krankenhaus, Auerbachstr. 110, Stuttgart, Germany 
3 Department of General Neurology and Hertie Institute for Clinical Brain Research, University of 
Tübingen, Hoppe-Seyler-Str. 3 Tübingen, Germany 
4 Dept. of Radiology and F.M. Kirby Center for Functional Brain Imaging, Kennedy Krieger Institute, 
Johns Hopkins University, 208 Traylor Bldg. 720, Rutland Ave. Baltimore, MD 21205 
5 Department of Physical Therapy and Rehabilitation Science, University of Maryland School of 
Medicine, 100 Penn St., Baltimore, MD 21201 
6 Div. of Brain Injury Outcomes, Department of Neurology, Johns Hopkins University, 1550 Orleans 
St., Baltimore, MD 21231 
 
Correspondence: 
Dr. Christoph Globas 
University Hospital of Zürich 
Department of Neurology 
Frauenklinikstr. 26 
CH-Zürich 
Switzerland 
Tel: +41 44 2555500 
Fax: +41 44 2554507 
cglobas@web.de 
 
 
 
Abstract: 250 words 
Text: 2976 words 
Number of references: 40 
Number of tables: 1 
Number of figures: 3 
 
Key Words: stroke, corticospinal tract, lesion, impairment, rehabilitation therapy 
CST atrophy in chronic stroke – 2 
Abstract 
Objective: Stroke survivors with motor deficits often have pyramidal tract atrophy 
caused by degeneration of corticospinal fibres. It is hypothesized that the degree of 
atrophy correlates with deficit severity in chronic stroke state and predicts the 
response to rehabilitation training. 
Methods: A post-hoc analysis of 42 chronic stroke survivors (> 6 months) 
randomized to either 6 weeks of bilateral arm training (BATRAC) or dose-matched 
therapeutic exercises  (DMTE) were performed. Arm function was measured using 
the Fugl-Meyer (FM) and modified Wolf Motor Function Test (WMFT). Structural MRI 
was obtained to assess corticospinal tract (CST) atrophy by planimetric 
measurement of the mesencephalon (mesencephalic atrophy ratio, MAR). Fractional 
anisotropy (FA) was measured using diffusion tensor imaging (DTI) on the pontine 
level. Voxel-based lesion symptom mapping (VLSM) was used to determine the 
lesions associated with highest degrees of atrophy, The predictive value of CST 
atrophy on deficit and training response was analyzed. 
Results: CST atrophy predicted baseline motor arm function measured by FM and 
WMFT (FM: r=0.39, p=0.014; WMFT: r=-0.35, p=0.042), while there was only a trend 
for the correlation with FA (p<0.1). No measure of atrophy predicted response to 
either BATRAC or DMTE. CST atrophy was higher with larger lesions (r=-0.50, 
p=0.035) and those that affected the CST (r=-0.49, p=0.038). VLSM identified 
internal capsule lesions as being associated with highest CST atrophy (p<0.01).  
Conclusion: Larger lesions, internal capsule lesions and those overlapping the 
pyramidal tract are associated with greater CST atrophy. CST atrophy explains in 
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part the variability of baseline deficits but does not seem to predict the response to 
BATRAC or unilateral arm training. 
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Introduction 
Several rehabilitation techniques have proven effectiveness in stroke survivors even 
years after stroke [1-4]. Because therapy response is variable, there is a growing 
need for measures that predict the response of the individual subject.  
Bilateral arm training with rhythmic auditory cueing (BATRAC) is one therapy that 
improves arm function in some but not all subjects with chronic upper extremity 
deficits [2, 5-7]. Patients are trained for 6 weeks performing rhythmic movements with 
both arms. 
We hypothesized that therapy response is poor in subjects with marked corticospinal 
tract atrophy. Atrophy and morphological changes of the cerebral peduncles caused 
by Wallerian and transsynaptic degeneration of pyramidal tract fibres are often 
observed in chronic stroke survivors [8-12]. Wallerian degeneration (WD) is 
characterized by progressive degeneration of the distal portion of the injured axon 
and consecutively by degeneration of the myelin sheath and removal of myelin 
debris. While WD occurs fast in the peripheral nervous system (PNS) (within days to 
weeks), it is very slow (months to years) and incomplete in central nervous system 
(CNS) of mammals. Rapid clearance of myelin seems to result in an extracellular 
environment that promotes axon regeneration in the PNS, whereas in the CNS, the 
prolonged presence of myelin-associated inhibitors likely contributes to the failure of 
CNS axons to regenerate and consecutively leads to atrophy (for review see [13]. 
Because this process is very slow it may lead to a slowly progressive deterioration of 
function even long after a stroke. Preventing this decline is an important therapeutical 
target. 
Magnetic resonance imaging (MRI) can be used to determine the degree of atrophy 
and the structural integrity of the corticospinal tract (CST). A recent study showed 
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that the degree of mesencephalic pyramidal tract atrophy is a function of the extent of 
CST injury in the lesioned hemisphere [10]. Similarly, Warabi et al. [14] had observed 
a positive relationship between descending motor tract injury and the mesencephalic 
CST atrophy in chronic stroke. The same investigators later found evidence that 
patients with CST atrophy greater than 60% showed limited recovery of hand 
function [15]. But, reports on the relationship between CST atrophy and therapy 
response or deficit severity remain controversial [16-21].  
Diffusion tensor imaging (DTI) is an MRI technique often used to evaluate CST 
integrity by measuring the amount of directional diffusion of protons along white 
matter tracts (fractional anisotropy, FA). Two studies showed a correlation between 
DTI measures of CST atrophy, motor evoked potentials (MEP) as a measure of 
functional CST integrity and arm function in chronic stroke survivors [20, 22]. 
Additionally, Stinear and colleagues reported poor improvements after a 30-day 
upper extremity rehabilitation program in patients who had a high degree of CST 
damage on DTI (FA asymmetry index > 0.25) and absent MEPs [20, 22]. 
Here, several neuroimaging methods were combined to assess the relationship 
between CST atrophy, motor deficits at baseline and response to bilateral arm 
training (BATRAC) and unilateral arm training (DMTE). Voxel-based lesion symptom 
mapping (VLSM) was used to identify lesions that are associated with severe CST 
atrophy [23]. CST atrophy and integrity was determined by DTI and morphologically 
by measuring midbrain symmetry on axial MRI sections [14].  
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Material & Methods 
Study participants 
This report presents a post-hoc analysis of a single-centre, randomized, controlled 
trial comparing BATRAC and dose-matched therapeutic exercises (DMTE; unilateral 
arm training based on conventional physiotherapy) in their effects on arm function 
(Whitall et al, submitted). We analyzed 42 subjects that had undergone MRI scanning 
at baseline. Seventeen were in the BATRAC and 17 in the DMTE group. Eight 
participants dropped out during training after receiving baseline assessments and 
MRI scanning. Reasons for dropping out were medical complications, personal or 
social issues, and difficulty with transportation to the training site. While all subjects 
received anatomical MRI scans, DTI was acquired in 23 subjects. The remaining 
participants did not tolerate the additional scan time of DTI. Two DTI scans had to be 
excluded from the analysis because of movement artefacts.  
Subjects were enrolled in the trial if they had residual upper extremity hemiparesis 
following a single ischemic stroke equal or longer than 6 month prior to enrolment. All 
patients had the ability to initiate antigravity shoulder/elbow movement in flexion and 
extension in the transverse plane such that at least 3 inches of forward movement 
occurred. All participants had completed 3 to 6 months of conventional rehabilitation 
therapy. Inclusion criteria included adequate language and cognitive function to 
understand instructions. Patients with multiple clinical strokes, a history of other 
neurological disease, chronic pain, or emotional disorders were excluded. The study 
was conducted as part of the University of Maryland School of Medicine, National 
Institute on Aging– Claude D. Pepper Older Americans Independence Center in 
collaboration with the Division of Brain Injury Outcomes, Johns Hopkins University. 
All study participants provided written informed consent. The study was approved 
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from the ethics committees of the participating institutions (the University of Maryland 
School of Medicine, the Baltimore Veterans Affairs Medical Center, and the Johns 
Hopkins University School of Medicine). 
BATRAC Training 
BATRAC training consisted of hour-long therapy sessions (four 5-minute movement 
periods interspersed with 10-minute rest periods) 3 times per week for 6 weeks. 
Upon auditory cues at individually determined preferred rates of 0.67 to 0.97 Hz, 
participants pushed and pulled bilaterally, in synchrony or alternation, two T-bar 
handles sliding in the transverse plane. The control group received dose matched 
unilateral therapeutic exercise (DMTE) for the upper extremities over the same time 
period. DMTE involved 4 exercises based on neurodevelopmental principles [24], 
including thoracic spine mobilization, scapular mobilization, weight bearing with the 
paretic arm, and opening the hand with finger extension performed on the same 5-
minute schedule as BATRAC. This treatment emphasizes handling techniques that 
facilitate body and limbs to assume “normal” positions.  Participants were 
encouraged to actively move while performing the exercises. Participants were aware 
of the treatment differences, but did not know that DMTE was a control intervention; 
thus, subjects reasonably expected an improvement regardless of group. 
Assessments of impairment and function 
Upper extremity motor function was measured with the upper-extremity portion of the 
Fugl-Meyer Motor Performance Test (FM) [25] and the modified Wolf Motor Function 
Test [26] (WMFT). The mean time, which was required to perform the 14 tasks of the 
WMFT with the paretic arm and hand, was used in statistical analyses. Maximum 
time allowed for each task was 120 seconds. Assessments were conducted at a 
location separate from the training site and carried out by a tester (same person each 
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time) blinded to group assignment. 
 
MRI Data Acquisition and Analysis 
MRI scanning was performed with a 1.5 T scanner (Philips, Eindhoven, Netherlands) 
at the Kirby Center for Functional Brain Imaging, Kennedy Krieger Institute, 
Baltimore, MD, USA. Scanning was performed within two weeks before the start of 
training. 
A T1-weighted sequence (3D-MPRAGE sequence; resolution 1x1x1 mm3, whole 
brain coverage) was used to measure the mesencephalic asymmetry ratio (MAR) 
and to characterize lesion location and size. The MAR was used to quantify CST 
atrophy at the level of the mesencephalon. The sizes of the left and the right 
mesencephalon were measured planimetrically on an axial slice. The axial slice was 
parallel to the plane through the mamillary body and the posterior commissure. The 
axial slice was positioned mid-way between mamillary body and upper rim of the 
pons. Planimetric measurements were conducted using Medical Image Processing, 
Analysis and Visualization software (MIPAV, Version 3.1.6; [27]. MAR was defined as 
the ratio of affected to unaffected side. 
Voxel- Based Lesion- Symptom Mapping (VLSM) 
For Voxel-Based Lesion-Symptom Mapping (VLSM) [23] T1-weighted images were 
transformed into Talairach space [28] by rotation and scaling using Brain Voyager 
QX software (Brain Innovation BV, Maastricht, The Netherlands). Binary lesion 
masks were produced based on T1-weighted scans by manually segmenting the 
lesion area. Areas of CSF intensity and hypodense regions at the boundary were 
combined to define the lesion. Lesion size was derived from the lesion mask by 
multiplying the number of voxels with voxel volume (1 mm3). Manual segmentation 
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was performed using MRIcro (Chris Rorden, University of Nottingham, Great Britain). 
Masks with right-hemisphere lesions were flipped so that the lesion was always on 
the left. The binary lesion masks of each subject were entered into the voxel-based 
lesion symptom mapping software (VLSM, http://crl.ucsd.edu/vlsm, based on Matlab, 
Mathworks Inc., Natick, MA, USA). For each of these voxels, subjects were divided 
into two groups, whether or not that voxel was included in the lesion mask. To keep 
the number of subjects in those groups sufficient for statistical comparisons, only 
voxels that were part of three or more lesion masks were considered. The MAR 
values for both groups were then compared using t-tests resulting in a t-value for 
each voxel. The colour-coded map of the t-values of all voxels was then overlaid onto 
a healthy brain template using a threshold of p≤0.05. Brain regions with significant t-
values were localized using the Talairach daemon [29]. 
Assessment of direct CST injury 
To measure the degree of CST injury the overlap of each stroke lesion with the CST 
was determined counting the number of common voxels in the lesion mask and a 
CST region of interest (ROI). The CST ROI was obtained from a DTI-based fibre tract 
atlas in Talairach space [30]. In addition to the absolute number of common voxels, 
the percent overlap was calculated as the quotient between common voxel number 
and the number of all voxels in the CST ROI. 
Diffusion tensor imaging (DTI) 
DTI data were acquired using a single-shot, echo-planar imaging (EPI) sequence 
with sensitivity encoding (SENSE, parallel-imaging factor of 2.5 [31]). The imaging 
matrix was 96 X 96 with a field-of-view of 240 x 240 mm (nominal resolution, 2.5 
mm), zero-filled to 256 X 256 pixels. Transverse sections of 2.5 mm thickness were 
acquired parallel to the anterior commissure-posterior commissure line. A total of 50-
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55 sections covered the entire brain and brainstem without gaps. Diffusion weighting 
was encoded along 30 independent orientations [32], and the b-value was 700 
s/mm2. Five additional images with minimal diffusion weighting (b ≈ 33 s/mm2) were 
also acquired. To enhance the signal-to-noise ratio, this protocol was repeated three 
times. Fractional anisotropy (FA) of pontine corticospinal tract fibres was measured 
to assess CST integrity as described in detail elsewhere [33]. The FA ratio was built 
between FA of unlesioned and lesioned CST. To allow for a comparison with other 
studies [e.g. 20], lateralization indices were also calculated for FA (difference over 
the sum ((FA unlesioned – FA lesioned) / FA unlesioned + FA lesioned). 
Statistical analyses 
To assess therapy response general linear models were used to predict the change 
in outcome variables (FM, WMFT) across time (difference post-pre), one for each 
variable. Independent variables included group (comparison BATRAC vs. DMTE) 
and the baseline value of the respective dependent variable. Additionally within group 
comparisons were (paired t-test; difference in test performance: post- – pre- training) 
were conducted for each group. General linear modeling was used to determine 
lesion parameters associated with CST atrophy and to analyze the predictive value of 
lesion and atrophy parameters for baseline deficit and therapy response. Separate 
models were computed for each dependent variable, CST atrophy, baseline WMFT, 
baseline FM, change in WMFT and change in FM over the training period. 
Independent variables were CST atrophy (MAR, for baseline deficit and therapy 
response models), lesion size, lesion location (cortical versus subcortical), time since 
stroke, age and CST damage (overlap between lesion and CST). Separate models 
were computed to test the influence of FA on the dependent variables, because DTI 
data was only available in a subset of patients. Independent variables were entered 
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and removed from the models in a stepwise fashion using p<0.25 as entry and then 
p>0.05 are a criterion for removal. Interactions were included in the model and 
removed if insignificant. Data are expressed as meanstandard deviation. A 2-tailed 
p< 0.05 was considered significant.  
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Results 
The results of the parent randomized-controlled trial about the efficacy of BATRAC 
therapy versus DMTE will be reported elsewhere. Briefly, significant improvements in 
FM and modified WMFT were shown for both groups without between group 
differences. Basic demographic and clinical characteristics of the study participants 
are provided in Table 1. While all patients included here underwent FM testing 
(n=42), WMFT scores were only available in 36 patients. In the present sample of 34 
patients (BATRAC/DMTE= 17/17) in which MRI scans as well as baseline and post-
training functional data were available, there was a significant improvement in WMFT 
in the BATRAC group (-2.9±2.4 s; range: +3.6 to -12,9 s; t=2.79; degrees of freedom 
(df)=16; p=0.01) and a trend of improved function in FM score for BATRAC 
(+0.94±2.9 points; range: -2 to +5; t=-1.36; df=16; p=0.19) and in both FM and WMFT 
in DMTE (+1.3±3; range: -3 to 5; t=-1.77; df=16; p=0.1 respectively -3.0±5.3s; range: 
+1.8 – 13.0 s; t=-1.9; df=10; p=0.1). Repeated measures ANOVA revealed no 
significant time-by-group interactions for both measures (FM: F(1,32)=0.12; p=0.73; 
WMFT: F(1,26)=0.001; p=0.98) (see table 1). 
Lesion profiles predicting CST atrophy 
In addition to a correlation between CST damage (overlap CST-lesion) and lesion 
size (cortical: r=0.73, p=0.0001; subcortical: r=0.89, p<0.0001), both variables 
independently predicted CST atrophy, i.e., MAR (size: r=-0.50, p=0.035, CST 
overlap: r=-0.49, p=0.038, Figure 1). Both factors together explained 31% of the 
variability of MAR. Interactions between lesion size, CST damage and lesion location 
(cortical versus subcortical) were insignificant and removed from the model. Lesion 
location, age and time since stroke did not explain the variability of MAR. For those 
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subjects in whom DTI was available, FA-ratio did not correlate significantly with MAR 
(r=0.1). 
VLSM analysis was used to identify lesion patterns that were associated with CST 
atrophy (n=42). VLSM can only identify those brain regions that are lesioned in 3 or 
more subjects in the sample. Within this compound brain area (Figure 2A) lesions in 
the internal capsule were statistically related to higher degree of ipsilesional CST 
atrophy (t=2.522, p<0.01) (Figure 2B). 
CST atrophy, baseline function and therapy response 
High CST atrophy predicted low arm function (baseline FM score: r=0.39; p=0.014, 
WMFT time: r=-0.35, p=0.042, Figure 3). FA was not significantly related to baseline 
arm function but trends were noted for both baseline FM score (ratio: r=0.4, p=0.06; 
lateralisation index: r=-0.41, p=0.051) and baseline WMFT (ratio: r=-0.43, p=0.09; 
lateralisation index: r=0.46, p=0.08). No parameter characterizing lesion morphology 
(size, location, CST overlap) and atrophy (MAR, FA) predicted therapy response in 
the BATRAC, DMTE groups or in all subjects combined. 
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Discussion 
CST atrophy measured at the level of the mesencephalon occurs with larger cortical 
or subcortical lesions affecting the CST. While chronic upper extremity motor deficits 
are associated with high degrees of CST atrophy, atrophy does not influence 
response to BATRAC or DMTE in chronic stroke survivors. 
Warabi et al. [14] reported an association between lesion size and location and 
mesencephalic atrophy in 89 chronic stroke survivors. Mark et al. [10], however, did 
not find infarct size to predict atrophy in their sample of 34 chronic stroke survivors 
but reported that CST atrophy was related to the degree of overlap CST damage 
(CST-lesion overlap) as we observed in our sample. Consistent with this observation 
is the VLSM analysis that identified lesions in the internal capsule, i.e., subcortical 
lesions strategically affecting the CST, to be specifically prone to produce CST 
atrophy. Our data also show a relationship between the size of cortical strokes and 
CST atrophy (Figure 2A) indicating that large cortical lesions also cause atrophy. It 
has to be mentioned, that one limitation of planimetric measurement of 
mesencephalic peduncular atrophy is, that it does not encompass the CST 
exclusively and results might be influenced by degeneration of other cortigofugal 
tracts as well. 
Larger lesions themselves seem to be associated with more severe deficits in the 
acute phase as well as three months after stroke [34-38]. Some reports, including 
ours in chronic stroke however, have not found this relationship [39, 40]. Certainly, 
lesion location influences the size-deficit relationship. Direct correlations may only 
exist as long as lesions within the same functional brain system are compared [15, 
36, 38, 41]. For example, it is known from clinical practice that even larger lesions 
affecting or extending into frontal areas may be clinically silent, at least if patients are 
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not intensively tested neuropsychologically. Therefore, the combination of size and 
location (“lesion profile”) may be required to determine deficits and prognosis [35, 
37].  
Although the lesion profile did not predict deficit severity here, CST atrophy did. This 
observation is in accordance with the results of two recent studies [20, 22]. However, 
the conclusion that atrophy causes arm impairment is premature, because disuse of 
the arm as a consequence of the initial deficit may have contributed to CST atrophy. 
No lesion or atrophy parameter predicted response to BATRAC or DMTE. One 
previous report showed less benefit from a 30-day unilateral upper extremity training 
program including active and passive practices in chronic stroke survivors with 
greater CST damage determined by DTI and dysfunction assessed using transcranial 
magnetic stimulation (TMS) [20]. Differences in clinical baseline impairment and the 
degree of CST disintegration – subjects in the study of Stinear et al. had markedly 
lower baseline FM scores (16±7.3 vs. 31.9±12.5) and greater CST damage than our 
subjects – may explain contrasting results. Stinear et al. reported predictive effects 
only for patients in whom no MEPs were evoked by transcranial magnetic 
stimulation. Those patients showed an FA lateralization index > 0.25 and did not 
improving at all. We cannot exclude that a similar association exists in a subset of 
our patients as we have no MEP data and only 3 patients (13%) had an FA index > 
0.25. Thus, it may be that only severe atrophy may negatively affect therapy 
response. The benefit of rehabilitation therapies may additionally be determined by 
the ability of the non-lesioned brain to undergo functional reorganization or 
neuroplasticity [5]. Consequently, factors predicting therapy response may be found 
in unaffected rather than lesioned brain at least for bilateral training. Alternatively, 
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reorganization may involve cortical and subcortical networks that exclude the 
mesencephalon. 
Fractional anisotropy showed only a trend towards an association with motor deficits. 
This may either be the consequence of low statistical power due to a small sample or 
may reflect methodological limitations, e.g., DTI being very sensitive to motion 
artefacts. 
 
In conclusion, this study suggests that larger lesions and those that affect the CST 
are associated with severe CST atrophy at the level of the mesencephalon. CST 
atrophy predicts deficit severity in chronic stroke survivors. CST atrophy seems to 
have no negative effect on bilateral or unilateral rehabilitation training, which is 
reassuring for this highly affected group of individuals. 
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Table 1. Baseline characteristics and therapy response 
 BATRAC (n=17) DMTE (n=17) ALL (n=42)  p-value 
Age (years) 60.6±13.7 56.2±14.6 60.4±14.1 0.371 
Gender (f/m) 9/8 10/7 22/20 0.732 
Time since stroke (months) 45.3±37.9 47.5±43.6 44.4±38.1 0.881 
Stroke Side (left/right) 7/10 7/10 16/26 1.02 
Location:    0.722 
Cortical 9 7 22  
Subcortical 7 8 16  
Brainstem 1 2 4  
MAR 0.8±0.14 0.78±0.17 0.81±0.15 0.71 
FA ratio 0.81±0.18 0.74±0.12 0.77±0.16† 0.261 
FA lateralisation index 0.1±0.1 0.16±0.1 0.13±0.1† 0.161 
Functional scores 
(Baseline) 
    
FM 31.9±12.5 28.3±12.4 32.5±12.9 0.41 
WMFT (time; s) 52.6±38.7 56.6±38.0 48.3±36.8 0.81 
Functional change**   (n=34)  
FM 0.94±2.9 1.3±3 1.1±2.9 0.733 
WMFT (time; s) -2.9±2.4* -3.0±5.3 -2.95±4.7 0.983 
1 between group comparison (t-test; BATRAC vs. DMTE) 
2 Fisher Exact Test 
3 MANOVA (time*group interaction; BATRAC vs. DMTE) 
† N=23 
* within group comparison (paired-T) significant by p<0.05) 
** Functional change= therapy response as defined by the difference of scores: post – pre training 
 
 
CST atrophy in chronic stroke – 23 
 
 
Figure 1. Relationship between lesion size and mesencephalic atrophy ratio (MAR) 
for cortical and subcortical lesions in all subjects (n=42). Lower MAR values indicate 
higher degrees of atrophy. 
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Figure 2. (A) overlay of all lesions included in the sample (n=42), (B) voxels 
predicting high degrees of CST atrophy (p<0.01).  
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Figure 3. Correlation between arm function and CST atrophy in all subjects (n=42). 
Lower MAR values, i.e. higher atrophy, are associated with lower FM scores, i.e. 
lower arm function. 
 
 
 
